226 related articles for article (PubMed ID: 33112294)
1. THERAPY OF ENDOCRINE DISEASE: Endocrine-metabolic effects of treatment with multikinase inhibitors.
Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Camastra S; Mazzi V; Miccoli M; Benvenga S; Antonelli A
Eur J Endocrinol; 2021 Jan; 184(1):R29-R40. PubMed ID: 33112294
[TBL] [Abstract][Full Text] [Related]
2. Endocrine-related adverse conditions induced by tyrosine kinase inhibitors.
De Leo S; Trevisan M; Moneta C; Colombo C
Ann Endocrinol (Paris); 2023 May; 84(3):374-381. PubMed ID: 36963756
[TBL] [Abstract][Full Text] [Related]
3. Thyroid dysfunctions induced by tyrosine kinase inhibitors.
Fallahi P; Ferrari SM; Vita R; Di Domenicantonio A; Corrado A; Benvenga S; Antonelli A
Expert Opin Drug Saf; 2014 Jun; 13(6):723-33. PubMed ID: 24821006
[TBL] [Abstract][Full Text] [Related]
4. Expert opinion on the metabolic complications of new anticancer therapies: Tyrosine kinase inhibitors.
Buffier P; Bouillet B; Smati S; Archambeaud F; Cariou B; Verges B
Ann Endocrinol (Paris); 2018 Oct; 79(5):574-582. PubMed ID: 30174137
[TBL] [Abstract][Full Text] [Related]
5. Expert opinion on thyroid complications of new anti-cancer therapies: Tyrosine kinase inhibitors.
Drui D; Illouz F; Do Cao C; Caron P
Ann Endocrinol (Paris); 2018 Oct; 79(5):569-573. PubMed ID: 30126626
[TBL] [Abstract][Full Text] [Related]
6. Endocrine side-effects of anti-cancer drugs: thyroid effects of tyrosine kinase inhibitors.
Illouz F; Braun D; Briet C; Schweizer U; Rodien P
Eur J Endocrinol; 2014 Sep; 171(3):R91-9. PubMed ID: 24833135
[TBL] [Abstract][Full Text] [Related]
7. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
Miyake H; Imai S; Harada K; Fujisawa M
Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
[TBL] [Abstract][Full Text] [Related]
8. Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society.
Arima H; Iwama S; Inaba H; Ariyasu H; Makita N; Otsuki M; Kageyama K; Imagawa A; Akamizu T
Endocr J; 2019 Jul; 66(7):581-586. PubMed ID: 31243183
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.
Worden F; Fassnacht M; Shi Y; Hadjieva T; Bonichon F; Gao M; Fugazzola L; Ando Y; Hasegawa Y; Park DJ; Shong YK; Smit JW; Chung J; Kappeler C; Meinhardt G; Schlumberger M; Brose MS
Endocr Relat Cancer; 2015 Dec; 22(6):877-87. PubMed ID: 26370187
[TBL] [Abstract][Full Text] [Related]
10. Therapy of endocrine disease: response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis.
Klein Hesselink EN; Steenvoorden D; Kapiteijn E; Corssmit EP; van der Horst-Schrivers AN; Lefrandt JD; Links TP; Dekkers OM
Eur J Endocrinol; 2015 May; 172(5):R215-25. PubMed ID: 25572389
[TBL] [Abstract][Full Text] [Related]
11. Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?
Wang S; Yang Z; Wang Z
Oncotarget; 2015 Jul; 6(20):18206-23. PubMed ID: 26156021
[TBL] [Abstract][Full Text] [Related]
12. Practical management of tyrosine kinase inhibitor-associated side effects in GIST.
Joensuu H; Trent JC; Reichardt P
Cancer Treat Rev; 2011 Feb; 37(1):75-88. PubMed ID: 20570050
[TBL] [Abstract][Full Text] [Related]
13. Managing tyrosine kinase inhibitors side effects in thyroid cancer.
Krajewska J; Paliczka-Cieslik E; Jarzab B
Expert Rev Endocrinol Metab; 2017 Mar; 12(2):117-127. PubMed ID: 30063430
[TBL] [Abstract][Full Text] [Related]
14. Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma.
Rimassa L; Danesi R; Pressiani T; Merle P
Cancer Treat Rev; 2019 Jul; 77():20-28. PubMed ID: 31195212
[TBL] [Abstract][Full Text] [Related]
15. Endocrine side effects of broad-acting kinase inhibitors.
Lodish MB; Stratakis CA
Endocr Relat Cancer; 2010 Sep; 17(3):R233-44. PubMed ID: 20603395
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis.
Makita N; Iiri T
Thyroid; 2013 Feb; 23(2):151-9. PubMed ID: 23398161
[TBL] [Abstract][Full Text] [Related]
17. How tyrosine kinase inhibitors impair metabolism and endocrine system function: a systematic updated review.
Breccia M; Molica M; Alimena G
Leuk Res; 2014 Dec; 38(12):1392-8. PubMed ID: 25449685
[TBL] [Abstract][Full Text] [Related]
18. Patterns of thyroid hormone levels in pediatric medullary thyroid carcinoma patients on vandetanib therapy.
Lodish M; Gkourogianni A; Bornstein E; Sinaii N; Fox E; Chuk M; Marcus L; Akshintala S; Balis F; Widemann B; Stratakis CA
Int J Pediatr Endocrinol; 2015; 2015(1):3. PubMed ID: 25972901
[TBL] [Abstract][Full Text] [Related]
19. Practical recommendation for rash and diarrhea management in Indian patients treated with tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
Parikh P; Prabhash K; Naik R; Vaid AK; Goswami C; Rajappa S; Noronha V; Joshi A; Chacko RT; Aggarwal S; Doval DC
Indian J Cancer; 2016; 53(1):87-91. PubMed ID: 27146751
[TBL] [Abstract][Full Text] [Related]
20. The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors.
Ye L; Santarpia L; Gagel RF
Endocr Rev; 2010 Aug; 31(4):578-99. PubMed ID: 20605972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
